Old | New | Differences | |
---|---|---|---|
1 | - | An Act | |
2 | - | ENROLLED HOUSE | |
1 | + | ||
2 | + | ||
3 | + | SENATE FLOOR VERSION - HB2424 SFLR Page 1 | |
4 | + | (Bold face denotes Committee Amendments) 1 | |
5 | + | 2 | |
6 | + | 3 | |
7 | + | 4 | |
8 | + | 5 | |
9 | + | 6 | |
10 | + | 7 | |
11 | + | 8 | |
12 | + | 9 | |
13 | + | 10 | |
14 | + | 11 | |
15 | + | 12 | |
16 | + | 13 | |
17 | + | 14 | |
18 | + | 15 | |
19 | + | 16 | |
20 | + | 17 | |
21 | + | 18 | |
22 | + | 19 | |
23 | + | 20 | |
24 | + | 21 | |
25 | + | 22 | |
26 | + | 23 | |
27 | + | 24 | |
28 | + | ||
29 | + | SENATE FLOOR VERSION | |
30 | + | April 13, 2023 | |
31 | + | ||
32 | + | ||
33 | + | ENGROSSED HOUSE | |
3 | 34 | BILL NO. 2424 By: May of the House | |
4 | 35 | ||
5 | 36 | and | |
6 | 37 | ||
7 | 38 | Stephens of the Senate | |
8 | - | ||
9 | - | ||
10 | 39 | ||
11 | 40 | ||
12 | 41 | ||
13 | 42 | ||
14 | 43 | An Act relating to opioid antagonists; amending 63 | |
15 | 44 | O.S. 2021, Section 1 -2506.2, which relates to | |
16 | 45 | prescription of opioid antagonists to family members; | |
17 | 46 | replacing naloxone with opioid antagonist; amending | |
18 | 47 | 63 O.S. 2021, Section 2 -312.2, which relates to the | |
19 | 48 | sale or dispensation of naloxone; removing naloxone | |
20 | 49 | and replacing it with opioid antagonist; and | |
21 | 50 | providing an effective d ate. | |
22 | 51 | ||
23 | 52 | ||
24 | 53 | ||
25 | 54 | ||
26 | - | SUBJECT: Opioid antagonists | |
27 | - | ||
28 | 55 | BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: | |
29 | - | ||
30 | 56 | SECTION 1. AMENDATORY 63 O.S. 2021, Section 1 -2506.2, is | |
31 | 57 | amended to read as follows: | |
32 | - | ||
33 | 58 | Section 1-2506.2 A. Upon request, a provider may prescribe an | |
34 | 59 | opiate opioid antagonist to an individual for use by that individual | |
35 | 60 | when encountering a family member exhibiting signs of an opiate | |
36 | 61 | opioid overdose. | |
37 | - | ||
38 | 62 | B. When an opiate opioid antagonist is prescribed in accordance | |
39 | 63 | with subsection A of this section, the provider shall provide: | |
40 | - | ||
41 | 64 | 1. Information on how to spot symptoms of an overdose; | |
42 | - | ||
43 | 65 | 2. Instruction in basic resuscitation techniques; | |
44 | 66 | ||
67 | + | SENATE FLOOR VERSION - HB2424 SFLR Page 2 | |
68 | + | (Bold face denotes Committee Amendments) 1 | |
69 | + | 2 | |
70 | + | 3 | |
71 | + | 4 | |
72 | + | 5 | |
73 | + | 6 | |
74 | + | 7 | |
75 | + | 8 | |
76 | + | 9 | |
77 | + | 10 | |
78 | + | 11 | |
79 | + | 12 | |
80 | + | 13 | |
81 | + | 14 | |
82 | + | 15 | |
83 | + | 16 | |
84 | + | 17 | |
85 | + | 18 | |
86 | + | 19 | |
87 | + | 20 | |
88 | + | 21 | |
89 | + | 22 | |
90 | + | 23 | |
91 | + | 24 | |
92 | + | ||
45 | 93 | 3. Instruction on proper naloxone opioid antagonist | |
46 | - | administration; and ENR. H. B. NO. 2424 Page 2 | |
47 | - | ||
94 | + | administration; and | |
48 | 95 | 4. The importance of calling 911 nine-one-one (911) for help. | |
49 | - | ||
50 | 96 | C. Any family member administering an opiate opioid antagonist | |
51 | 97 | in a manner consistent with addressing opiate opioid overdose shall | |
52 | 98 | be covered under the Good Samaritan Act. | |
53 | - | ||
54 | 99 | D. Any provider prescribing o r administering an opiate opioid | |
55 | 100 | antagonist in a manne r consistent with addressing opiate opioid | |
56 | 101 | overdose shall be covered under the Good Samaritan Act. | |
57 | - | ||
58 | 102 | SECTION 2. AMENDATORY 63 O.S. 2021, Section 2 -312.2, is | |
59 | 103 | amended to read as follows: | |
60 | - | ||
61 | 104 | Section 2-312.2 Naloxone, also known as Narcan , or any of its | |
62 | 105 | generic equivalents Any opioid antagonist that is approved by the | |
63 | 106 | United States Food and Drug Admini stration may be dispensed or sold | |
64 | 107 | by a pharmacy without a prescription; provided, however, it shall be | |
65 | 108 | dispensed or sold only by, or under t he supervision of, a licensed | |
66 | 109 | pharmacist. Naloxone An opioid antagonist may be prescribed and | |
67 | 110 | dispensed by a licens ed pharmacist; provided, however, it shall be | |
68 | 111 | dispensed only by, or under the supervision of, a licensed | |
69 | 112 | pharmacist. No dispensing protocol shall be required. | |
70 | - | ||
71 | 113 | SECTION 3. This act shall become effective November 1, 2023. | |
72 | - | ||
73 | - | ||
74 | - | ENR. H. B. NO. 2424 Page 3 | |
75 | - | Passed the House of Representati ves the 13th day of March, 2023. | |
76 | - | ||
77 | - | ||
78 | - | ||
79 | - | ||
80 | - | Presiding Officer of the House | |
81 | - | of Representatives | |
82 | - | ||
83 | - | ||
84 | - | Passed the Senate the 19th day of April, 2023. | |
85 | - | ||
86 | - | ||
87 | - | ||
88 | - | ||
89 | - | Presiding Officer of the Senate | |
90 | - | ||
91 | - | ||
92 | - | ||
93 | - | OFFICE OF THE GOVERNOR | |
94 | - | Received by the Office of the Governor this ____________________ | |
95 | - | day of ___________________, 20_______, at _______ o'clock _______ M. | |
96 | - | By: _________________________________ | |
97 | - | Approved by the Governor of the State of Oklahoma this _____ ____ | |
98 | - | day of ___________________, 20_______, at _______ o'clock _______ M. | |
99 | - | ||
100 | - | ||
101 | - | _________________________________ | |
102 | - | Governor of the State of Oklahoma | |
103 | - | ||
104 | - | OFFICE OF THE SECRETARY OF STATE | |
105 | - | Received by the Office of the Secretary of State this __________ | |
106 | - | day of ___________________, 20_______, at _______ o'clock _______ M. | |
107 | - | By: _________________________________ | |
114 | + | COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES | |
115 | + | April 13, 2023 - DO PASS |